CareRx Corporation
TSX:CRRX.TOMedical - Care Facilities
+$0.02 today
- Market cap
- $203.06M
- Beta
- 0.62
- P/E (TTM)
- 7.4
- EPS (TTM)
- $0.43
- Dividend yield
- 1.88%
Volume 0.01M
Average 0.04M
CRRX.TO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CareRx CorporationTSX: CRRX.TO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of CA$1.17M rose 415.0% year over year, behind the +820.5% change in trailing-twelve-month net income. Sequentially, it fell 95.1% from the prior quarter.
Context
- Net income amounted to 7.1% of revenue in FY2025, up 5.8 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of CA$4.5M (-82.8%) for the fiscal year ending Dec 2026, a slowdown from the +680.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$1.17M-95.1% QoQ
- Last fiscal yearDec 2025
- CA$26.13M+680.5% YoY
- LTMMar 2026
- CA$27.07M+820.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +415.0% | +166.7% | -248.3 pp |
| 1 year | +680.5% | -82.8% | -763.3 pp |
| 3-year CAGR | — | -20.5% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the cash flow
- Latest · FY2025
- 26.13M CAD
- Year-over-year change
- +680.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.13M | +680.5% |
| FY2024 | 2024-12-31 | (4.5M) | +16.7% |
| FY2023 | 2023-12-31 | (5.41M) | +84.3% |
| FY2022 | 2022-12-31 | (34.35M) | -51.1% |
| FY2021 | 2021-12-31 | (22.73M) | — |
Net Income vs competitors
How CRRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +820.5% is the highest of 6, against a peer median of -42.7%.
- Net income amounts to 7.2% of revenue for CRRX.TO, versus a peer median of 19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $38.94M USD | +20.4% | +14.1% | 207.6% |
| LTM Mar 2026 | CA$33.21M CAD | +52.5% | — | 20.9% | |
| LTM Mar 2026 | $33.14M USD | -68.8% | +19.7% | 10.9% | |
| LTM Mar 2026 | CA$27.07M CAD | +820.5% | — | 7.2% | |
| LTM Mar 2026 | $10.31M USD | -42.7% | -19.2% | 18.5% | |
| LTM Apr 2026 | CA$3.32M CAD | -65.1% | -7.4% | — | |
| Peer median (excluding CRRX.TO) | — | -42.7% | +3.3% | 19.7% | |
Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.73M) | (34.35M) | (5.41M) | (4.5M) | 26.13M |
| Depreciation & Amortization | 15.39M | 20.07M | 19.98M | 19.19M | 18.33M |
| Deferred Income Tax | (1.01M) | (1.54M) | (4.19M) | 32K | (22.77M) |
| Stock-Based Compensation | 2.67M | 4.57M | 1.47M | 3.65M | 2.72M |
| Change in Working Capital | (3.73M) | 638K | 2.12M | 8.98M | (988K) |
| Accounts Receivables | (11.72M) | 1.51M | 1.47M | 3.82M | 247K |
| Inventory | (2.83M) | (2M) | 648K | 1.55M | (126K) |
| Accounts Payables | 15M | 816K | (181K) | 3.46M | (891K) |
| Other Working Capital | (4.17M) | 307K | 186K | 145K | (218K) |
| Other Non-Cash Items | 16.67M | 32.96M | 13.4M | 10.64M | 4.12M |
| Operating Cash Flow | 7.27M | 22.33M | 27.38M | 37.99M | 27.54M |
| Capital Expenditures | (7.12M) | (13.61M) | (8.7M) | (8.11M) | (5.59M) |
| Acquisitions (Net) | (86.13M) | (2.99M) | (3.66M) | 196K | 39K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 67K | (3.57M) | (3.93M) | (2.53M) | 0 |
| Investing Cash Flow | (93.18M) | (16.6M) | (12.31M) | (7.92M) | (8.26M) |
| Debt Repayment | 30.35M | (5.29M) | (39.82M) | (21.58M) | (4.32M) |
| Common Stock Issued | 80.86M | 1.01M | 14.68M | 0 | 14K |
| Common Stock Repurchased | 0 | 0 | (56K) | (801K) | (2.24M) |
| Dividends Paid | 0 | 0 | 0 | 0 | (1.26M) |
| Other Financing Activities | (9.3M) | (8.71M) | (11.2M) | (5.64M) | (6.64M) |
| Financing Cash Flow | 101.91M | (12.99M) | (36.4M) | (28.02M) | (14.44M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16M | (7.25M) | (21.34M) | 2.06M | 4.84M |
| Free Cash Flow | 153K | 8.72M | 18.68M | 29.88M | 21.95M |
CareRx Corporation
TSX:CRRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.